Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Universal Beteiligungs und Servicegesellschaft mbH

Universal Beteiligungs und Servicegesellschaft mbH raised its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.4% in the third quarter, Holdings Channel.com reports. The fund owned 108,044 shares of the biopharmaceutical company’s stock after purchasing an additional 1,486 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH’s holdings in Regeneron Pharmaceuticals were worth $60,750,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Chicago Partners Investment Group LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $531,000. Grey Fox Wealth Advisors LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter worth $93,000. Seizert Capital Partners LLC boosted its position in shares of Regeneron Pharmaceuticals by 14.9% during the third quarter. Seizert Capital Partners LLC now owns 98,790 shares of the biopharmaceutical company’s stock worth $55,547,000 after buying an additional 12,810 shares during the period. Sage Mountain Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at $514,000. Finally, Jackson Thornton Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter valued at $519,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages recently commented on REGN. Wells Fargo & Company raised their target price on Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the company an “equal weight” rating in a report on Wednesday, December 10th. Guggenheim raised their price objective on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. Cantor Fitzgerald upped their target price on shares of Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. Scotiabank increased their target price on shares of Regeneron Pharmaceuticals from $650.00 to $770.00 and gave the stock a “sector perform” rating in a report on Monday, November 24th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 29th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $791.05.

Regeneron Pharmaceuticals Stock Up 2.1%

Shares of NASDAQ:REGN opened at $749.33 on Thursday. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $821.11. The firm’s 50 day moving average price is $752.97 and its 200 day moving average price is $640.77. The company has a quick ratio of 3.33, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The stock has a market cap of $78.75 billion, a price-to-earnings ratio of 17.94, a price-to-earnings-growth ratio of 1.92 and a beta of 0.39.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, beating analysts’ consensus estimates of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. During the same period in the prior year, the firm posted $12.46 EPS. The company’s quarterly revenue was up .9% compared to the same quarter last year. As a group, equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, December 5th. Investors of record on Thursday, November 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is 8.43%.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the sale, the director directly owned 1,703 shares of the company’s stock, valued at $1,362,400. The trade was a 46.83% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the transaction, the vice president directly owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 8,431 shares of company stock worth $5,733,521 over the last ninety days. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.